CSPC
CSPC
Biomedical R&D company
CSPC, founded in June, 1992 and headquartered in Shijiazhuang, is a biopharmaceutical developer. The founder is Cai Dongchen. Listed on the HKEX on June 21, 1994, the company's major shareholders are Massive Top. Limited. Rivals that have direct and indirect competition with CSPC include 111 Group, JD health, Glaxo Smith Kline, Pfizer, etc.
- All
- News
- Analysis
- Research
Briefing Jun 24, 2022 11:15 AM
· Healthcare
F-star to be acquired by China biopharmaceutical with USD 161million
Briefing Jun 24, 2022 11:07 AM
· Healthcare
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
In-depth
Healthcare
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Briefing Jun 24, 2022 10:46 AM
· Healthcare
East China medicine "liraglutide" goes to sea
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Research
Consumer Staples, Healthcare, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Briefing Jun 23, 2022 06:25 PM
· Healthcare
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Briefing Jun 23, 2022 06:24 PM
· Healthcare
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Briefing Jun 23, 2022 10:36 AM
· Healthcare
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Briefing Jun 23, 2022 10:27 AM
· Healthcare
Yanye new crown drug 3CL protein inhibitor has been suspended approval
In-depth
Healthcare
Immunotherapy in China: A Rising Star in the Field of Cancer Treatment
Immunotherapy is emerging as a powerful weapon in fighting cancer by restarting and maintaining the cancer-immunity cycle to identify, control and eliminate tumor cells rather than killing them directly.
Nov 24, 2022 06:29 PM
Briefing Jun 23, 2022 10:24 AM
· Healthcare
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
Briefing Jun 23, 2022 10:22 AM
· Healthcare
Acadia Alzheimer's drug SNDA application rejected by FDA advisory committee
Briefing Jun 23, 2022 10:20 AM
· Healthcare
Huashen Zhiyao completed nearly 500million yuan of a-round financing and went deep into AI new drug development
Insight
Healthcare
Challenges and Opportunities Possessed by Digital Therapeutics Industry
Following the digital therapeutics series report, this article is centered on the challenges and opportunities faced by the digital therapeutics industry and aims to provide insights on the two above aspects.
Nov 23, 2022 03:23 PM
Briefing Jun 23, 2022 10:15 AM
· Healthcare
Huamei Haolian, a health management service enterprise, completed round a+ financing, and Jinshajiang venture capital led the investment
Briefing Jun 23, 2022 10:06 AM
· Healthcare
Mojia biology announced the completion of round B financing
Briefing Jun 23, 2022 09:50 AM
· Healthcare
First class recall of Draeger, a ventilator giant
Briefing Jan 14, 2022 02:18 PM
· Healthcare
Hong Kong stocks continued to rise in the anti epidemic sector, and Junshi biology rose nearly 17%
See more
Related Companies
